Zacks Investment Research upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a sell rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
A number of other analysts have also recently commented on ASMB. BidaskClub cut Assembly Biosciences from a sell rating to a strong sell rating in a research report on Friday, July 13th. Robert W. Baird started coverage on Assembly Biosciences in a research report on Wednesday, August 8th. They issued an outperform rating and a $74.00 price target on the stock. ValuEngine cut Assembly Biosciences from a buy rating to a hold rating in a research report on Wednesday, October 3rd. Finally, B. Riley raised Assembly Biosciences from a neutral rating to a buy rating and set a $42.00 price target on the stock in a research report on Monday, October 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $62.60.
Shares of ASMB opened at $24.01 on Tuesday. Assembly Biosciences has a 52 week low of $23.05 and a 52 week high of $67.36. The company has a market capitalization of $945.08 million, a PE ratio of -9.96 and a beta of 0.80.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.42). Assembly Biosciences had a negative return on equity of 66.34% and a negative net margin of 457.20%. The company had revenue of $3.22 million during the quarter, compared to the consensus estimate of $3.30 million. On average, research analysts predict that Assembly Biosciences will post -4.12 earnings per share for the current year.
In related news, VP Uri A. Lopatin sold 15,204 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $40.09, for a total value of $609,528.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Derek A. Small acquired 2,400 shares of the firm’s stock in a transaction that occurred on Thursday, July 19th. The stock was purchased at an average price of $41.48 per share, with a total value of $99,552.00. Following the completion of the acquisition, the chief executive officer now owns 668,091 shares in the company, valued at $27,712,414.68. The disclosure for this purchase can be found here. 18.20% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ASMB. Bank of Montreal Can purchased a new position in Assembly Biosciences in the 2nd quarter worth approximately $145,000. Quantbot Technologies LP purchased a new position in Assembly Biosciences in the 1st quarter worth approximately $154,000. Jane Street Group LLC purchased a new position in Assembly Biosciences in the 1st quarter worth approximately $204,000. MetLife Investment Advisors LLC purchased a new position in Assembly Biosciences in the 2nd quarter worth approximately $282,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in Assembly Biosciences in the 2nd quarter worth approximately $348,000. Institutional investors own 65.21% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Recommended Story: Moving Average – How it Helps Investors in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.